Clinical Research Directory
Browse clinical research sites, groups, and studies.
Levothyroxine Supplementation for Heart Transplant Recipients
Sponsor: University of California, San Francisco
Summary
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Official title: Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
97
Start Date
2024-03-29
Completion Date
2027-03-01
Last Updated
2025-05-01
Healthy Volunteers
No
Interventions
Levothyroxine
Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
Normal saline
Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Locations (1)
University of California, San Francisco
San Francisco, California, United States